References in periodicals archive ?
Disulfiram may thus prove to be effective against leishmaniasis.
Florez favors acamprosate and topiramate for alcohol craving, naltrexone for the purpose of reducing the "priming" phenomenon (in which some patients experience an increased desire for alcohol after a single drink) and disulfiram for reducing alcohol intake.
In rats, a combination of levodopa, benserazide, and disulfiram injected intraperitoneally increases striatal contents of DOPAL to about 2 ng/mg protein (about 13 pmol/mg), without a semichronic effect on striatal dopamine contents after repeated injections (10).
Alcoholism treatment by disulfiram and community reinforcement counseling.
Use of an alcohol-containing mouth rinse in persons taking disulfiram (Antabuse[R]) and metronidazole (Flagyl[R]) is contraindicated because, in combination, they may induce nausea, vomiting and other unpleasant side effects.
Coverage includes the use of CM interventions to promote abstinence from commonly abused drugs such as cocaine, marijuana, methamphetamine, alcohol, the opioids, and smoked nicotine; the use of CM to enhance compliance with pharmacological treatments, such as disulfiram and naltrexone; the use of CM across a range of populations, including adolescents, pregnant women, homeless individuals, and people with mental illness; and review and discussion of the encouraging, rapidly expanding, and widespread dissemination of CM approaches to substance abuse treatment.
The study of alcohol-dependent patients included healthcare utilization variables for 20,752 patients, half of whom used an FDA-approved medication for alcohol dependence - VIVITROL, oral naltrexone, oral disulfiram or oral acamprosate - and half of whom had not used one of these medications.
In contrast, disulfiram did not consistently reduce any measure of alcohol consumption or improve any alcohol-related health outcome.
3% should not be used concomitantly with or within 2 weeks of disulfiram treatment.
Disulfiram has been used for decades to treat alcohol dependence; naltrexone was first approved by the Food and Drug Administration (FDA) in 1984 as a treatment for opioid dependence and then later (in 1994) as an adjunct to the treatment of alcohol dependence; and buprenorphine was approved by the FDA for treatment of opioid dependence in 2002.
2005), naltrexone, disulfiram, or a combination of both was added to treatment as usual.
Among four medications studied, use of Vivitrol was associated with fewer inpatient detox days than use of oral naltrexone, disulfiram (Antabuse), or acamprosate (Campral), and fewer alcoholism-related inpatient days than disulfiram or acamprosate.